Blog

Novel ways to mitigate the toxicity associated with combination therapy for EGFR-mutant advanced NSCLC – ESMO

ESMO/LinkedIn

Mar 27, 2025, 14:29

Novel ways to mitigate the toxicity associated with combination therapy for EGFR-mutant advanced NSCLC – ESMO

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“Two studies presented at ELCC25 highlight novel ways to mitigate the toxicity associated with combination therapy for EGFR-mutant advanced NSCLC.

The ETOP AMAZE-lung phase II Clinical Trial sought to provide an alternative to amivantamab plus chemotherapy for patients after progression on osimertinib. Amivantamab, lazertinib and bevacizumab demonstrated modest yet durable efficacy with manageable toxicity.
In the COCOON trial, skin adverse events were significantly reduced using a prophylactic enhanced dermatologic regimen compared with standard dermatologic management following the initiation of first-line amivantamab plus lazertinib.

Julien MAZIERES comments on these findings in the ESMO Daily Reporter.”

Amivantamab Bevacizumab cancer chemotherapy COCOON trial EGFR ESMO ESMODailyReporter ETOP AMAZE European Society for Medical Oncology fight against cancer Global fight against cancer Julien Mazières lazertinib NSCLC OncoDaily Oncology osimertinib

Meet the New AACR Board of Directores for 2025-2028 Term

Do Artificial Sweeteners Cause Cancer? Myths and Facts

King Charles III Hospitalized Following Side Effects from Cancer Treatment

Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026

MARIPOSA trial results presented at ELCC25 - BREAKING from Paris